Abstract
This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Graphical Abstract
Current Drug Targets
Title:New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases
Volume: 19 Issue: 16
Author(s): Ales Tichy, Jan Marek, Radim Havelek*, Jaroslav Pejchal, Martina Seifrtova, Lenka Zarybnicka, Alzbeta Filipova, Martina Rezacova and Zuzana Sinkorova
Affiliation:
- Department of Medical Biochemistry, Faculty of Medicine in Hradec Kralove, Charles University, 500 03 Hradec Kralove,Czech Republic
Keywords: PUMA, ionizing radiation, small molecule inhibitor, radioprotection, hearth, brain.
Abstract: This review summarizes recent progress in understanding the role of p53-upregulated mediator of apoptosis (PUMA) in molecular pathways with respect to its potential therapeutic applications. Particular emphasis is given to the PUMA´s role in ionizing radiation-induced signalling as radiotoxicity of normal tissue is mediated mostly via apoptosis. PUMA and its p53-dependent and p53- independent induction are described and potential use as a new target for the development of radioprotective agents is suggested. Further implications, including targeting PUMA to prevent and treat cardiovascular and neurodegenerative diseases, are also discussed together with an overview of other therapeutic applications. Finally, basic chemical structures for the development of novel PUMA modulators such as pifithrine derivatives, kinase inhibitors or modulators of Bcl-2 protein family are described.
Export Options
About this article
Cite this article as:
Tichy Ales , Marek Jan, Havelek Radim *, Pejchal Jaroslav , Seifrtova Martina , Zarybnicka Lenka , Filipova Alzbeta , Rezacova Martina and Sinkorova Zuzana , New Light on An Old Friend: Targeting PUMA in Radioprotection and Therapy of Cardiovascular and Neurodegenerative Diseases, Current Drug Targets 2018; 19 (16) . https://dx.doi.org/10.2174/1389450119666180406110743
DOI https://dx.doi.org/10.2174/1389450119666180406110743 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Metal Complexes, their Cellular Targets and Potential for Cancer Therapy
Current Pharmaceutical Design Defensin Participation in Innate and Adaptive Immunity
Current Pharmaceutical Design Aspartic Proteases in Drug Discovery
Current Pharmaceutical Design Targeting Tumor Microenvironment with Silibinin: Promise and Potential for a Translational Cancer Chemopreventive Strategy
Current Cancer Drug Targets Synthesis and Antiproliferative Activity of New Coumarin-Based Benzopyranone Derivatives Against Human Tumor Cell Lines
Medicinal Chemistry Nanotherapeutics in Tumour Microenvironment for Cancer Therapy
Nanoscience & Nanotechnology-Asia New and Under Explored Epigenetic Modulators in Search of New Paradigms
Medicinal Chemistry Beyond Hemostasis: The Role of Platelets in Inflammation, Malignancy and Infection
Cardiovascular & Hematological Disorders-Drug Targets Protein Secretome Analysis of Evolving and Responding Tumor Ecosystems
Current Proteomics Metallothioneins and Platinum(II) Anti-Tumor Compounds
Current Medicinal Chemistry VEGF in Tumor Progression and Targeted Therapy
Current Cancer Drug Targets Proline Oxidase (POX) as A Target for Cancer Therapy
Current Drug Targets Cholinergic Targets in Lung Cancer
Current Pharmaceutical Design Prognostic Parameters in Myeloid Malignancies in a Historical Context – From Microscopy to Individualized Medicine
Current Drug Targets Potential Anticancer Properties of Bisphosphonates: Insights From Preclinical Studies
Anti-Cancer Agents in Medicinal Chemistry Targeting Tumor Suppressor p53 for Cancer Therapy: Strategies, Challenges and Opportunities
Current Drug Targets Receptor Selective Synthetic Retinoids as Potential Cancer Chemotherapy Agents
Current Cancer Drug Targets Antiproliferative and Proapoptotic Effects of the TrK-inhibitor GW441756 in Human Myosarcomas and Prostatic Carcinoma
Current Signal Transduction Therapy Stem Cell Transplantation and MBL Replacement Therapy
Current Stem Cell Research & Therapy